Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04762537 · ClinicalTrials.gov registry record · NA
Surmounting Withdrawal to Initiate Fast Treatment With Naltrexone
A NA study, sponsored by New York State Psychiatric Institute.
- Completed
- Registry status
- NA
- Development phase
- 415
- Enrollment target
NCT04762537: Completed NA study, sponsored by New York State Psychiatric Institute.
NCT04762537 is a NA study that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 415 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (70% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04762537, a NA study, has completed, sponsored by New York State Psychiatric Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 415 participants
- Enrollment target
Study Summary
This study compares two methods of initiating treatment with extended-release naltrexone (XR-NTX) when implemented at community-based inpatient or residential programs. The primary goal of this hybrid effectiveness-implementation study is to determine whether the Rapid Method (5-7 day long) is non-inferior to a Standard Method (13-day long) on the primary effectiveness outcome of successful initiation of XR-NTX (receiving the first injection). Secondary objectives include comparing Rapid versus Standard method on: time from admission to first dose of XR-NTX and time to dropout, craving, withdrawal severity, retention, abstinence, and safety measures, as measured during the inpatient induction process and the first two months of post-induction XR-NTX maintenance. Other exploratory outcomes include predictors of initiation success, and economic analyses. The implementation goal is to operationalize an implementation facilitation strategy that will be used to train clinical sites on the XR-NTX initiation method, to capture fidelity to the rapid induction process, and to study barriers and facilitators to implementation and refine the implementation facilitation strategy accordingly.
Primary Outcome
The primary goal of the study is to show RP is non-inferior to SP XR-NTX induction method.
Interventions
- OTHER Standard Induction Procedure (SP)
- OTHER Rapid Induction Procedure (RP)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 415 participants |
| Start Date | 2021-03-16 |
| Est. Completion | 2022-12-21 |
| Phase | NA |
What the finished NCT04762537 record still lists
NCT04762537 is an interventional study that assigns participants to a tested intervention. The registered 415 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (70% lower).
The record links to 0 conditions, and to 2 interventions - of which Standard Induction Procedure (SP) is the first listed.
NCT04762537 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04762537 about?
NCT04762537 is a clinical study titled "Surmounting Withdrawal to Initiate Fast Treatment With Naltrexone". This study compares two methods of initiating treatment with extended-release naltrexone (XR-NTX) when implemented at community-based inpatient or residential programs. The primary goal of this hybrid effectiveness-implementation study is to determine whether the Rapid Method (5-7 day long) is non-i...
What is the current status of trial NCT04762537?
This trial is currently completed. It is a NA study. The enrollment target is 415 participants. The study started on 2021-03-16. Estimated completion is 2022-12-21.
What interventions are being tested in trial NCT04762537?
The interventions under investigation include: Standard Induction Procedure (SP) (OTHER), Rapid Induction Procedure (RP) (OTHER).
Who is sponsoring clinical trial NCT04762537?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04762537's enrollment target sits among peer trials
415 241st of 2000 higher than 1,760 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05142605 · 415 participants · NA
Evaluation of Grief Therapy Approaches for Bereaved Parents
- NCT03527537 · 416 participants · Phase 4
Gestational Diabetes and Pharmacotherapy (GAP)
- NCT05007782 · 416 participants · Phase 1
Study of Denikitug (GS-1811) Given Alone or With Zimberelimab in Adults With Advanced Solid Tumors
- NCT05520099 · 416 participants
Observational Basket Trial to Collect Tissue to Develop and Train a Live Tumor Diagnostic Platform
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI